Literature DB >> 29675847

Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias.

Raffaella Origa1, Antonio Piga2, Immacolata Tartaglione3, Giuseppina Della Corte4, Gian Luca Forni5, Andreas Bruederle6, Chiara Castiglioni7, Jackie Han8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29675847     DOI： 10.1002/ajh.25122

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

Review 1.  Iron Chelators in Treatment of Iron Overload.

Authors:  Sarina Entezari; Seyedeh Mona Haghi; Narges Norouzkhani; Barsa Sahebnazar; Fatemeh Vosoughian; Diba Akbarzadeh; Muhammad Islampanah; Navid Naghsh; Mohammad Abbasalizadeh; Niloofar Deravi
Journal:  J Toxicol       Date:  2022-05-05

Review 2.  Deferasirox: Over a Decade of Experience in Thalassemia.

Authors:  Nour M Moukalled; Rayan Bou-Fakhredin; Ali T Taher
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-11-01       Impact factor: 2.576

Review 3.  Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.

Authors:  Valeria Maria Pinto; Gian Luca Forni
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.